| Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma X Zhang, T Zegar, T Weiser, FH Hamdan, BT Berger, R Lucas, ... International Journal of Cancer 147 (10), 2847-2861, 2020 | 36 | 2020 |
| Discovery of nanomolar-affinity pharmacological chaperones stabilizing the oncogenic p53 mutant Y220C JR Stephenson Clarke, LR Douglas, PJ Duriez, DI Balourdas, AC Joerger, ... ACS pharmacology & translational science 5 (11), 1169-1180, 2022 | 32 | 2022 |
| The role of E3, E4 ubiquitin ligase (UBE4B) in human pathologies N Antoniou, N Lagopati, DI Balourdas, M Nikolaou, A Papalampros, ... Cancers 12 (1), 62, 2019 | 25 | 2019 |
| Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog Q Zhang, DI Balourdas, B Baron, A Senitzki, TE Haran, KG Wiman, ... Cell death & disease 13 (3), 214, 2022 | 14 | 2022 |
| Structure–Reactivity Studies of 2-Sulfonylpyrimidines Allow Selective Protein Arylation MM Pichon, D Drelinkiewicz, D Lozano, R Moraru, LJ Hayward, M Jones, ... Bioconjugate Chemistry 34 (9), 1679-1687, 2023 | 8* | 2023 |
| Shifting the selectivity of pyrido [2, 3-d] pyrimidin-7 (8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily M Rak, R Tesch, LM Berger, E Shevchenko, M Raab, A Tjaden, R Zhubi, ... European Journal of Medicinal Chemistry 254, 115347, 2023 | 5 | 2023 |
| Lipophilic guanylhydrazone analogues as promising trypanocidal agents: an extended SAR study V Pardali, E Giannakopoulou, DI Balourdas, V Myrianthopoulos, ... Current pharmaceutical design 26 (8), 838-866, 2020 | 5 | 2020 |
| Development of potent dual BET/HDAC inhibitors via pharmacophore merging and structure-guided optimization N Bauer, DI Balourdas, JR Schneider, X Zhang, LM Berger, BT Berger, ... ACS chemical biology 19 (2), 266-279, 2024 | 4 | 2024 |
| Functional diversity of the TP53 mutome revealed by saturating CRISPR mutagenesis J Funk, M Klimovich, E Pavlakis, M Neumann, D Drangenstein, ... bioRxiv, 2023.03. 10.531074, 2023 | 4 | 2023 |
| Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors M Rak, A Menge, R Tesch, LM Berger, DI Balourdas, E Shevchenko, ... Journal of Medicinal Chemistry 67 (5), 3813-3842, 2024 | 2 | 2024 |
| Synthesis of pyrazole-based macrocycles leads to a highly selective inhibitor for MST3 JA Amrhein, LM Berger, DI Balourdas, AC Joerger, A Menge, A Krämer, ... Journal of Medicinal Chemistry 67 (1), 674-690, 2023 | 1 | 2023 |
| Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators DI Balourdas, AM Markl, A Krämer, G Settanni, AC Joerger Cell Death & Disease 15 (6), 408, 2024 | | 2024 |
| Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε FH de Souza Gama, LA Dutra, M Hawgood, CV Dos Reis, RAM Serafim, ... Journal of Medicinal Chemistry, 2024 | | 2024 |
| Novel dihydropteridinone derivatives as potent and selective inhibitors of the understudied human vaccinia-related kinase 1 (VRK1) FH de Souza Gama, L Dutra, M Hawgood, CV dos Reis, R Serafim, ... | | 2023 |
Andreas C. JoergerStructural Genomics Consortium (SGC), Institute of Pharmaceutical Chemistry, Goethe University在 pharmchem.uni-frankfurt.de 的电子邮件经过验证
